Myrcludex B, a novel therapy for chronic hepatitis D?

Affiliations

¹ Department of Internal Medicine - Gastroenterology, University of Torino, Italy. Electronic address: mario.rizzetto@unito.it.
² IRCCS "Casa Sollievo Sofferenza" Hospital, Gastroenterology Unit, San Giovanni Rotondo (FG), Italy.

Editorial

Mario Rizzetto et al. J Hepatol. 2016 Sep.

. 2016 Sep;65(3):465-6.

doi: 10.1016/j.jhep.2016.06.014.

¹ Department of Internal Medicine - Gastroenterology, University of Torino, Italy. Electronic address: mario.rizzetto@unito.it.
² IRCCS "Casa Sollievo Sofferenza" Hospital, Gastroenterology Unit, San Giovanni Rotondo (FG), Italy.

No abstract available

Comment on

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Bogomolov P, et al. J Hepatol. 2016 Sep;65(3):490-8. doi: 10.1016/j.jhep.2016.04.016. Epub 2016 Apr 27. J Hepatol. 2016. PMID: 27132170 Clinical Trial.
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.
Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. Blank A, et al. J Hepatol. 2016 Sep;65(3):483-9. doi: 10.1016/j.jhep.2016.04.013. Epub 2016 Apr 27. J Hepatol. 2016. PMID: 27132172